| 益赛普治疗强直性脊柱炎临床观察 |
| |
| 引用本文： | 尚桂莲.益赛普治疗强直性脊柱炎临床观察[J].中国医院药学杂志,2011(16). |
| |
| 作者姓名： | 尚桂莲 |
| |
| 作者单位： | 武汉科技大学附属天佑医院; |
| |
| 摘 要： | 目的:评价重组人Ⅱ型肿瘤坏死因子受体Fc抗体融合蛋白(益赛普)治疗强直性脊柱炎(AS)的疗效和安全性。方法:30例活动性AS患者随机分为治疗组(15例)和对照组(15例),分别应用益赛普(etanercept)、柳氮磺吡啶(SASP)均联合甲氨蝶呤(MTX)治疗12周,分别在第0,4,8,12周评价2组的临床疗效和安全性。观察指标为ASAS20、ASAS50、ASAS70、AS活动指数(BASDAI)、脊柱痛VAS评分、晨僵时间、胸廓扩张度、Schober试验、脊柱侧弯以及C反应蛋白(CRP)、红细胞沉降率(ESR)等。结果:治疗组患者治疗后BASDAI、脊柱痛、胸廓扩张度、Schober试验、脊柱侧弯及CRP、ESR等指标较治疗前均明显改善,差异均有统计学意义(P<0.05)。对照组患者治疗后BASDAI、脊柱痛、晨僵时间及CRP、ESR均较治疗前明显改善,差异均有统计学意义(P<0.05),但胸廓扩张度、Schober试验、脊柱侧弯治疗前后的差异无统计学意义。2组间比较,治疗组各项观察指标改善程度明显优于对照组,差异有统计学意义(P<0.05)。治疗组不良反应发生率(20%)明显低于对照组(53.3%),...
|
| 关 键 词： | 强直性脊柱炎 肿瘤坏死因子α 益赛普 |
Clinic observation on etanercept in treatment of ankylosing spondylitis |
| |
| SHANG Gui-lian.Clinic observation on etanercept in treatment of ankylosing spondylitis[J].Chinese Journal of Hospital Pharmacy,2011(16). |
| |
| Authors: | SHANG Gui-lian |
| |
| Institution: | SHANG Gui-lian(Department of Rheumatology,the Affiliated Hospital of Wuhan Techlology and Science,Hubei Wuhan 430064,China) |
| |
| Abstract: | OBJECTIVE To evaluate effects of etanercept on treating patients with ankylosing spondylitis.METHODS 30 cases of ankylosing spondylitis patients were divided into 2 groups according to resourceful principle.The patients in the control group were given sulfasalazin combined with methotrexat;the treatment group was given etanercept combined with methotrexat.Course of treatment was 12 weeks.ASAS20,ASAS50,ASAS70,BASDAI,spinal pain VAS,duration of morning stiffness,chest expansion,Schobers test,scoliosis test,CR... |
| |
| Keywords: | |
| 本文献已被 CNKI 等数据库收录！ |
|
